 | |||||||||||||||
 |
 |
 |
|
 |
|
 |
|
 |
|
 |
|
 |
|
 |
 |
News item posted on 2015-01-19
Fesik Lab forms multi-year alliance to develop cancer treatment
Vanderbilt University and Boehringer Ingelheim have established a multi-year alliance to research and develop small molecule inhibitors of oncogenic Ras for cancer treatment. CSB Investigator Stephen Fesik, Ph.D., will lead the research of new medicines for the Ras protein family at Vanderbilt. The alliance aim is to combine the techniques and expertise of the Fesik Lab and Boehringer Ingelheim to address what has been a difficult drug to target.
The Boehringer Ingelheim group is a world-leading pharmaceutical company headquartered in Germany. The company, founded in 1885, focuses on research, development, manufacturing and marketing new medications of high therapeutic value.
For more information, please read the Boehringer Ingelheim press release.
Congratulations to Dr. Fesik and the Fesik Lab!
Author: Karen D. Davis